遼寧成大(600739.SH)擬掛牌轉讓成大方圓100%股權
格隆匯5月8日丨遼寧成大(600739.SH)公佈,公司擬通過產權交易所公開掛牌競價轉讓遼寧成大所持成大方圓醫藥集團有限公司(以下簡稱“成大方圓”)100%的股權。
北京中企華資產評估有限責任公司出具了《遼寧成大股份有限公司擬轉讓持有的成大方圓醫藥集團有限公司股權涉及的成大方圓醫藥集團有限公司股東全部權益價值項目資產評估報告》(中企華評報字(2020)第3447號),該資產評估報告選用市場法評估結果作為評估結論。市場法評估後的股東全部權益評估價值為18.59億元。
本次交易的實施有利於公司優化資源配置,進一步聚焦核心主業,降低公司的經營風險和財務風險,更好地優化產業佈局,符合公司長期發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.